Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous versus intermittent intravenous magnesium replacement for prevention of atrial fibrillation in high-risk ICU patients
ACTRN12622001076763Phase 4Completed
- Sponsor
- Prof Rinaldo Bellomo
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of magnesium sulfate in Atrial fibrillation (AFib) (2 arms), sponsored by Prof Rinaldo Bellomo. Primary endpoint: Duration of new-onset atrial fibrillation. Started Feb 2023; status: completed.
02
Drugs
magnesium sulfate
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ACTRN12622001076763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001076763.